Cargando…
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108733/ https://www.ncbi.nlm.nih.gov/pubmed/21694902 http://dx.doi.org/10.2147/IDR.S7136 |
_version_ | 1782205362962694144 |
---|---|
author | Quer, Josep Buti, Maria Cubero, Maria Guardia, Jaume Esteban, Rafael Esteban, Juan Ignacio |
author_facet | Quer, Josep Buti, Maria Cubero, Maria Guardia, Jaume Esteban, Rafael Esteban, Juan Ignacio |
author_sort | Quer, Josep |
collection | PubMed |
description | Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development. The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies. Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects. |
format | Online Article Text |
id | pubmed-3108733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31087332011-06-21 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents Quer, Josep Buti, Maria Cubero, Maria Guardia, Jaume Esteban, Rafael Esteban, Juan Ignacio Infect Drug Resist Review Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development. The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies. Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects. Dove Medical Press 2010-11-23 /pmc/articles/PMC3108733/ /pubmed/21694902 http://dx.doi.org/10.2147/IDR.S7136 Text en © 2010 Quer et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Quer, Josep Buti, Maria Cubero, Maria Guardia, Jaume Esteban, Rafael Esteban, Juan Ignacio New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title_full | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title_fullStr | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title_full_unstemmed | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title_short | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
title_sort | new strategies for the treatment of hepatitis c virus infection and implications of resistance to new direct-acting antiviral agents |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108733/ https://www.ncbi.nlm.nih.gov/pubmed/21694902 http://dx.doi.org/10.2147/IDR.S7136 |
work_keys_str_mv | AT querjosep newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents AT butimaria newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents AT cuberomaria newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents AT guardiajaume newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents AT estebanrafael newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents AT estebanjuanignacio newstrategiesforthetreatmentofhepatitiscvirusinfectionandimplicationsofresistancetonewdirectactingantiviralagents |